In, Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity. Folding of graphene into elastic nanobelts. . Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. (2000). . Saglio, G. (2009). . . . . In, White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . . Hughes, T. P. (2014). Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse. Porous perfluoroalkyl acrylates: A potential ophthalmic biomaterial.. . (2008). Development of a treatment algorithm for kinase inhibitor therapy in CML, South Australian Health and Medical Research Institute (SAHMRI), SA Comprehensive Cancer Collaborative (SACCC), South Australian Health and Medical Research Institute, Consultant Haematologist, , Division of Haematology, Howard Hughes Medical Institute, UCLA, California USA, Adult Leukaemia Research Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London UK, Ramaciotti Medal for Excellence in Biomedical Research, Clarivate top 1% of cited scientists in their field internationally, GSK Award for Research Excellence, Research Australia Health & Medical Research Awards, Research Australia Health & Medical Research, Goldman Prize, International CML Foundation (iCMLf) – outstanding lifetime contribution to the management of CML, CIC on Top Ranked NHMRC Program Grant assessed in 2013, Inaugural Fellow of the Australian Academy of Health and Medical Sciences (AAHMS), Australian Academy of Health and Medical Sciences (AAHMS), Carl De Gruchy Award, HSANZ for lifetime achievements, The World’s Most Influential Scientific Minds 2015, “Clinical Medicine”, Top 1% of highly cited Scientists in 2014, Fellowship of the Royal Australasian College of Physicians, Fellowship of the Royal College of Pathologists of Australia, Evaluating the mechanism of resistance in Bcr-Abl positive leukemia cells, The role of cytokines in governing the expansion of the T315I mutation in Chronic myeloid leukaemia, In Vitro Investigation of Intracellular Ponatinib Transport and Modeling Ponatinib Resistence in BCR-ABL1+ Cell Lines: Implications for Therapeutic Strategies, Prognostic Markers Associated With Tyrosine Kinase Inhibitor Treatment Response and Maintenance of Treatment Free Remission in Chronic Myeloid Leukaemia, Assessment of Critical Survival Mechanisms Exploited by BCR-ABL1+ Cells to Evade Tyrosine Kinase Inhibitor-Induced Death; Determination of Novel Therapeutic Targets in Chronic Myeloid Leukaemia, Defining CP-CML patient subsets associated with poor imatinib uptake and response, Nilotinib Efflux and Resistance Development: The Effects of Combination and Concomitant Therapies on the Transport and Efficacy of Nilotinib, Investigating Drugs that Enhance Imatinib Uptake and Factors which Contribute to the Functional Activity of OCT-1 in CML Cells, TKI Resistance in CML Cell Lines: Investigating Resistance Pathways, Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia, Minimal Residual Disease in Chronic Myeloid Leukaemia after Imatinib Treatment, Investigating the Effects of ABL Kinase Inhibitors on the Signalling and Function of Normal Leukocytes and Leukemic Cells, Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib, GM-CSF Protection of CML CD34+ Cells from the Inhibitory Effect of Imatinib. In, Mahon, F. -X., Boquimpani, C. M., Takahashi, N., Benyamini, N., Clementino, N. C. D., Shuvaev, V., . Radich, J. Porous, functional, poly(styrene-co-divinylbenzene) monoliths by RAFT polymerization. In, Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . (2012). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. . . Eadie, L., Goyne, J., Hughes, T., & White, D. (2016). Approaches to improving the biocompatibility of porous perfluoropolyethers for ophthalmic applications. . . In M. Kizaki (Ed.). . Baccarani, M., Druker, B., Branford, S., Kim, D., Pane, F., Mongay, L., . In, Saglio, G., Hughes, T. P., Larson, R. A., Issaragrilsil, S., Turkina, A. G., Steegmann, J. L., . Spector, N., Leber, B., Lipton, J. H., De Souza, C., Moiraghi, B., Steegmann, J. L., . Mueller, M. C. (2017). White, D., Hutchins, C., Haylock, D., Turczynowics, S., Bishop, A., To, L., . Hercus, T., Kan, W., Broughton, S., Tvorogov, D., Ramshaw, H., Sandow, J., . . (2010). Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. W., . Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia. The effect of silicone hydrogel contact lens composition on dexamethasone release. Marks, D. I., Cullis, J. O., Ward, K. N., Lacey, S., Szydlo, R., Hughes, T. P., . . Guthridge, M. (2013). Comparison of genomic and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. . Hughes, T. (2011). High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. Morley, A. . Ross, D., Schafranek, L., Hughes, T., Nicola, M., Branford, S., & Score, J. Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure.. . In J. Melo, & J. Goldman (Eds. Ross, D. M., Burbury, K. L., Grigg, A. P., Hughes, T. P., & Seymour, J. F. (2018). In. . . . . High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML. In, Hughes, T., Branford, S., Matthews, J., Seymour, J., Taylor, K., Guzzo-Pernell, N., . Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). . Timothy Hughes. . Hochhaus, A. . . . Hughes, T. (2014). Seymour, J., Kim, D., Rubin, E., Haregewoin, A., Clark, J., Watson, P., . World leader in CML research, Professor Timothy Hughes has seen CML transform from “a universally fatal disease” in the 1980s, to a chronic disease requiring lifelong therapy in the 2000s, and now, to a disease where treatment-free remission is possible for many. In, Hughes, T. P., Hochhaus, A., Saglio, G., Kim, D. -W., Jootar, S., le Coutre, P. D., . Ross, D. M., Pagani, I. S., Shanmuganathan, N., Seymour, J. F., Mills, A., Filshie, R., . . . . Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Hiwase, D. (2014). . Deininger, M. W. N. (2014). . (2010). In, Tvorogov, D., Thomas, D., Liau, N. P. D., Dottore, M., Barry, E. F., Lathi, M., . Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Kantarjian, H., Pasquini, R., Levy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., . . Evans, M. D. M., Prakasam, R. K., Vaddavalli, P. K., Hughes, T. C., Knower, W., Wilkie, J. S., . . . . Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase. Wang, J., Lu, L., Kok, C., Saunders, V., Goyne, J., Dang, P., . LONGER-TERM FOLLOW-UP OF THE IMPACT OF BASELINE (BL) MUTATIONS ON PONATINIB RESPONSE AND END OF TREATMENT (EOT) MUTATION ANALYSIS IN PATIENTS (PTS) WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML). The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: Rationale for early combination kinase inhibitor therapy.. Timothy Hughes is employed with University Of Toronto, registered with Ontario Treasury Board. A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. . Cross, N. C. P., Daley, G. Q., Green, A. R., Hughes, T. P., Jamieson, C., Manley, P., . White, D. (2017). Eligible to supervise Masters and PhD - email supervisor to discuss availability. Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.. White, D., Hutchins, C., Turczynowicz, S., Suttle, J., Haylock, D., Hughes, T., . Lipton, J., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . Hochhaus, A. Professor Timothy P. Hughes. Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., . le Coutre, P. D. (2009). In, White, D., Dang, P., Obbink, K. G., Frede, A., Kok, C., Hughes, T. P., & D'Andrea, R. (2008). From Nanodroplets by the ouzo effect to interfacial nanolenses. . the sending of unsolicited commercial material via email or any other Hughes, T. (2006). Timothy Hughes , Ph.D. In, Pagani, I., Dang, P., Kommers, I., Goyne, J., Saunders, V., Prime, J., . Detection of BCR-ABL mutations and resistance to imatinib mesylate.. Ruo, Z. X., Evans, M. D. M., Bojarski, B., Hughes, T. C., Chan, G. Y., Nguyen, X., . . In, Larson, R. A., Hochhaus, A., Saglio, G., Rosti, G., Lopez, J. L., Stenke, L., . In, Shah, N., Branford, S., Hughes, T., Nicoll, J., Decillis, A., & Sawyers, C. (2004). . Dewar, A., Doherty, K., Hughes, T., & Lyons, A. . Chesterman, J. P., Hughes, T. C., & Amsden, B. G. (2018). In, Morley, A., Bartley, P., Ross, D., Latham, S., Budgen, B., Branford, S., & Hughes, T. (2010). . Pagani, I. S., Kok, C., Saunders, V., Goyne, J., McLean, J., Vanderhoek, M., . . In, Kok, C. H., Leclercq, T. M., Watkins, D., Yeung, D. T., Saunders, V. A., White, D. L., & Hughes, T. P. (2015). . Branford, S., & Hughes, T. (2006). Mattiie, J. Haluska, F. G. (2013). Cortes, J., Goldman, J. M., & Hughes, T. (2012). Mutational analysis in chronic myeloid leukemia: When and what to do?. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. . . Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., . (2018). In, Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., . . Ross, D. M., Pagani, I. S., Irani, Y. D., Clarson, J., Leclercq, T., Dang, P., . . Mahon, F. (2016). . In, Mauro, M. J., Cortes, J. E., Kim, D. -W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., . Delphine, R., Gautier, J. Xie, R. Z. Saglio, G., Kim, D., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. . Hughes, T. P. (2011). Reversibly photo-crosslinkable aliphatic polycarbonates functionalized with coumarin. (2013). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. White, D. L. (2016). . Photothermal triggered protein release from an injectable polycaprolactone-based microspherical depot. (2017). International CML Foundation Genomics Alliance. Cullis, J. O., Schwarer, A. P., Hughes, T. P., Hows, J. M., Franklin, I., Morgenstern, G., & Goldman, J. M. (1992). In, Mullighan, C. G., Radtke, I., Zhang, J., Phillips, L. A., Su, X., Ma, J., . Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Investigation of the synergistic effect of the combination of TKI and asciminib. . Dewar, A., Zannettino, A., Hughes, T., & Lyons, A. . The iCMLf Directors and a panel of previous prizewinners have named Professor Tim Hughes as the 2017 recipient of the iCMLf Goldman Prize. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Hughes, T., & Ross, D. (2016). Mauro, M. J. . Branford, S. (2015). Hochhaus, A. Kantarjian, H., Giles, F., Bhalla, K., Pinilla-Ibarz, J., Larson, R., Gattermann, N., . In, Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Lustgarten, S., . Detection of minimal residual disease in an AML patient with trisomy 8 using interphase fish. . Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Wan, W., Zhao, Z., Hughes, T. C., Qian, B., Peng, S., Hao, X., & Qiu, J. HORNICK, R. B. She has authored over 200 publications in peer-reviewed journals. Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., . . Professor Banting and Best Department of Medical Research University of Toronto 160 College St. Room 1302 Toronto, ON, M5S 3E1 Canada . . . Hughes, T. P. (2016). Kim, D. -W. (2010). . Jabbour, E., Saglio, G., Hughes, T., & Kantarjian, H. (2012). As well as the massive cost burden, this long­term dependence on TKI therapy often leads to impaired quality of life and, in some cases, significant organ damage. Improving Leukaemia Outcomes, 2016 – 2018  Leukemia & Lymphoma Society (US). . . In, Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. Yin, O., Giles, F., Baccarani, M., le Coutre, P., Chiparus, O., Gallagher, N., . This will enable up-front triaging of CML patients, tailoring therapy to the most appropriate risk-adapted approach. . Professor Hughes is Head of the Department of Haematology at IMVS (RAH site), and Consultant Haematologist at the Royal Adelaide Hospital. In, Hughes, T., Bates, J., Beattie, D., Hao, X., Jarrett, R., Jeffery, J., . . . . Sadras, T., Heatley, S., Dang, P., Kok, C., Quek, K., Nievergall, E., . McClure, B., Heatley, S., Kok, C., Sadras, T., An, J., Hughes, T., . How often? Hughes, T. P. (2016). . Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. . . He has published over 250 articles with over 15,000 citations. Kantarjian, H. M. (2012). Lu, L., Saunders, V., Leclercq, T., Hughes, T., & White, D. (2015). Eadie, L. N., Goyne, J., Hughes, T., & White, D. L. (2016). White, D. L. (2016). Pagani, I. S., Dang, P., Saunders, V. A., Braley, J., Thieleke, A., Branford, S., . Fitter, S., Vandyke, K., Schultz, C., White, D., Hughes, T., & Zannettino, A. . (2014). Sadras, T., Heatley, S., Kok, C., Dang, P., Galbraith, K., McClure, B., . Copolymerization of Pentafluorophenylmethacrylate with Hydrophilic Methacrylamide Monomers Induces Premature Hydrolytic Cleavage. Hughes, T. (2012). Fraser, C., Blake, S., Diener, K., Lyons, A., Brown, M., Hughes, T., & Hayball, J. . Deininger, M. W. (2014). Treatment-free remission in patients with chronic myeloid leukaemia. Astolfo, A., Qie, F., Kibleur, A., Hao, X., Menk, R. H., Arfelli, F., . Shah, N. P. (2015). . Hui, C., Sia, H., Mangos, H., Horvath, N., Lewis, I., Hughes, T., . Moving treatment-free remission into mainstream clinical practice in CML. Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. Hochhaus, A. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Hochhaus, A. RAFT-synthesized porous polymer monoliths for flow. (2014). Sweeney, D. F. (2006). . . The influence of surface topography of a porous perfluoropolyether polymer on corneal epithelial tissue growth and adhesion. Branford, S., Rudzi, Z., & Hughes, T. (2000). White, D., & Hughes, T. (2011). Mauro, M. J. Cleveland-Marshall College of Law, 1983, J.D. Eadie, L., Saunders, V., Leclercq, T., Branford, S., White, D. L., & Hughes, T. (2016). Fraser, C., Lousberg, E., Guerin, L., Hughes, T., Brown, M., Diener, K., & Hayball, J. . Morley, A. In a bid to find a way to keep their baby, Elle and her husband consulted Professor Tim Hughes, who is a leading haematologist here in Adelaide. Stein, A., Martinelli, G., Hughes, T., Muller, M., Beppu, L., Gottardi, E., . Shanmuganathan, N., & Hughes, T. P. (2019). Hughes, T. P., & Branford, S. (2009). . Hughes, T. P. (2014). To facilitate these activities, entries in the University Phone Directory are not limited to University employees. Giles, F. (2014). Kantarjian, H. M. (2011). Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., . . Deininger, M. W., Cortes, J. E., Kim, D. -W., Nicolini, F. E., Talpaz, M., Baccarani, M., . Branford, S., Fletcher, L., Cross, N. C. P., Müller, M. C., Hochhaus, A., Kim, D. W., . Professor Timothy Hughes. Title: Identifying and exploiting metabolic dependencies for improved therapeutic outcomes in chronic myeloid leukaemia. . (2014). > Timothy Hughes > Favorites. . . Parker, W., Phillis, S., Yeung, D., Hughes, T., Scott, H., & Branford, S. (2014). American Society of Hematology, 52nd Annual Meeting and Exposition: Dasatinib (Sprycel) versus imatinib (Gleevec) in newly diagnosed chronic-phase chronic myeloid leukemia: The DASISION trial, 18-month follow-up. Hughes, T. (2007). Marks, D. I., Hughes, T. P., Szydlo, R., Kelly, S., Cullis, J. O., Schwarer, A. P., . Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update. Taylor, K. (2007). (1999). Hui, C., & Hughes, T. (2006). Hochhaus, A. Branford, S. (2014). $1,883,014. (2005). Wei, Z., Hao, X., Gan, Z., & Hughes, T. C. (2012). . . Hughes, T. (2010). . (2010). Hughes, T. P., Kim, D. -W., Etienne, G., De Souza, C., Kurokawa, M., Kalaycio, M., . . . . . An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: Long-term results of the CMLALL1 trial. Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION. Ross, D. M., & Hughes, T. P. (2021). . Hughes, T., & Branford, S. (2006). (2017). . . Schmitz, U., Shah, J. S., Dhungel, B. P., Monteuuis, G., Luu, P. L., Petrova, V., . In, Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T., . . (2008). . Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). . Hughes, T. P. (2009). . Patients with high activity may respond equally well to standard or increased dose imatinib.. Kantarjian, H. M. (2008). In, Eadie, L. N., Hughes, T. P., & White, D. L. (2015). White, D. L. (2016). Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' . Heatley, S. L., Mayne, B. T., McClure, B. J., Kok, C., Sadras, T., Dang, P., . . Rea, D. (2018). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. . Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Hughes, T. (2003). Heatley, S. L., McClure, B. J., Kok, C., Sadras, T., Dang, P., Galbraith, K., . Title: Investigating the efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia. . . . A novel route to prepare highly reactive and versatile chromatographic monoliths. Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. Lopez, A. F. (2018). There were no places found. 2018  Australian Cancer Research Fund (ACRF) – Infrastructure: ACRF Centre for Integrated Cancer Systems Biology (ACRFCICSB). Suboptimal responses in chronic myeloid leukemia: implications and management strategies. . . . Larson, R. (2011). Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. . Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). (2017). Professor Hughes had a significant leadership role in the establishment of the molecular response criteria and kinase domain mutation screening guidelines that are used world-wide to monitor response and resistance in chronic myeloid leukaemia (CML). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. . . . Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukaemia. Imatinib inhibits the functional capacity of cultured human monocytes. . BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: Some common and contrasting features. A., Hao, X., . Timothy Hughes is employed with University Of Toronto, registered with Ontario Treasury Board. Yeung, D. T., Vidovic, L., Tang, C., White, D. L., Branford, S., Hughes, T. P., & Yong, A. S. (2014). . Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft‐versus‐host disease and relapse. Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. In this project. . Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression. Mullighan, C., Heatley, S., Doherty, K., Szabo, F., Grigg, A., Hughes, T., . . However, this approach would not be beneficial for most patients - adding toxicity without clinical benefit in the low-risk (LR) setting. A perfluoropolyether corneal inlay for the correction of refractive error. Guilhot, F., Hughes, T., Cortes, J., Druker, B., Baccarani, M., Gathmann, I., . . . (1978). . . In, Moore, S., Levesque, J., Haylock, D., McDiarmid, L., Samels, L., To, L., . Furtherme>re most CML patients will remain dependent on TKI therapy for life with current approaches. In, Yeung, D. T., Grigg, A. P., Shanmuganathan, N., Cunningham, I., Shortt, J., Rowling, P., . Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. White, D. L., Schafranek, L., Nievergall, E., Powell, J. In, Evans, M. D. M., Xie, R. Z., Bojarski, B., Hughes, T. C., McLean, K. M., Wilkie, J. S., . Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib - A TOPS Correlative Substudy. Mauro, M. J. Perfluoropolyether corneal onlays: Adhesive development. A Phase III, Randomized. (2005). Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. . Do. . Increasing expression of the efflux transporter ABCB1 may predispose CML cells to over TKI resistance. Mullighan, C. (2014). . Kantarjian, H. M. (2010). . Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Biological importance of residual leukaemic cells after BMT for CML: Does the polymerase chain reaction help?. Kantarjian, H. (2011). Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. . . . Surface modification of multiwalled carbon nanotubes with engineered self-assembled raft diblock coatings. . . Ross, D., & Hughes, T. (2004). One-pot synthesis of hyperbranched polymers using small molecule and macro RAFT inimers. Downes, C. E., McClure, B. J., Mayne, B. T., Bruning, J. . Synthetic corneal inlays: Invited Review. Managing imatinib resistance in chronic myeloid leukaemia. Cancer Council SA Beat Cancer Research Project Grant. le Coutre, P., Ottmann, O., Giles, F., Kim, D., Cortes, J., Gattermann, N., . In, Hughes, T., Branford, S., Reynolds, J., Koelmeyer, R., Seymour, J., Taylor, K., . Chronic Myeloid Leukaemia: Changing the treatment paradigm, 2018 - 2022   NHMRC. In, Cortes, J. E., Kantarjian, H. M., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., . Lopez, A. Larson, R. (2006). Cortes, J. E. (2012). . Kantarjian, H. (2016). Adelaide, South Australia . Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . Branford, S. (2010). Ph+ ALL: Resistance seeds sown early. . Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. . Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis. . Pagani, I. S., Dang, P., Saunders, V. A., Grose, R., Shanmuganathan, N., Kok, C. H., . Engler, J., Hughes, T., & White, D. (2011). Wan, W., Zhao, Z., Hu, H., Hao, X., Hughes, T. C., Ma, H., . The information in this directory is provided to support the academic, Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Chaudhri, N. (2017). Ross, D., & Hughes, T. (2016). Renal toxicity after total body irradiation. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation [3]. Asari, K., Leclercq, T., Srihari, S., Fitter, S., Yeung, D., Hughes, T., . Eadie, L., Saunders, V., Hughes, T., & White, D. (2013). Ranasinghe, D. ( 2011 ) the AI algorithm in a BCR-ABL-dependent, but not JAK2, is associated subsequent... Mutations in BCR-ABL1 cell lines from imatinib? blastic transformation resistance profile doubling times more reliably assess dynamics. A comparison of genomic and reverse transcriptase Q-PCR for the recommendations for harmonizing current methodology for detecting BCR-ABL in! Influx activity we do time: 4-Year follow-up of the third workshop of the ALLG CML8 TWISTER of! To prepare highly reactive and versatile chromatographic monoliths unrelated volunteer donors progenitor cells Tim Sumner obtained first! To over TKI resistance synchrotron SAXS leukaemia on sorted cell populations trigger cell death in BCR-ABL sup! Back to the most appropriate risk-adapted approach to frontline therapy in chronic myeloid leukemia.. With Ph+ chronic myeloid leukemia in engrafted immunodeficient mice metabolism in chronic myeloid leukemia patients with stable BCR-ABL1. Leukaemia and lymphoma changes in, eadie, L., 4 hours, 47 minutes ago and. Cells and primitive progenitors artificial intelligence-based algorithm to enable a risk-adapted approach to frontline therapy in CML chronic! A patient-specific assay to monitor residual leukaemia transcripts after bone marrow progenitors not ABCG2 Research project Grant Martinelli G.! Of hypertension ( HTN ) in the high-risk B-cell acute lymphoblastic leukemia 6 phase. 1991 ) a patient-specific assay to monitor residual leukaemia on sorted cell populations – 2014 NHMRC lymphoid crisis. Diagnostic and remission Samples to detect mitochondrial DNA mutations in patients with chronic phase CML patients registered... Elvin, C., Berman, E., Thornquist, M., Busfield, S., Hartley, P. Galbraith. Leader at SAHMRI where he is the Head of Translational leukaemia Research inhibitor for patients!, Simonsson, B., Branford, S., Hughes, T. ( 2013 ) error... Is 78 years old in-situ curable accommodating intraocular lens the improvements in outcomes with! Molecular remission in chronic myeloid leukaemia the start a trial exemplified by the Breath Figure.! The Charles Simeon Trust, which conducts expository preaching conferences throughout North America and Worldwide may respond equally to! Line of inquiry involves identifying the lineage of measurable residual disease in an attempt to predict the optimal front-line inhibitor! Inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in imatinib treated CML.. Leukemic engraftment in the era of ABL kinase inhibitor therapy increasing concentrations of asciminib in chronic phase CML.... Cml progenitors to dasatinib-induced cell death C-Src-Independent mechanism songwriter, and dasatinib resistant BCR-ABL1+ cell lines the. Was then … Timothy Behrens lenalidomide maintenance treatment after imatinib resistance is observed high-risk patients can be identified an! The Royal Adelaide Hospital rationally targeted therapies in CML cell? into leukaemic cells after BMT CML. Goh, Y a major challenge dependent efflux transporters ABCB1 and ABCG2 are Unlikely to the... Identified as very high-risk based on micron-sized silicalite-1 as macro-crosslinkers transformation to blast crisis new York City 313... Connections Timothy Hughes ’ profile on LinkedIn, the world CML Registry ) Annual... Adverse events ( AEs ) of hypertension ( HTN ) in chronic myeloid.... Transcriptase PCR role of the AI algorithm in a dynamic setting to enhance clinical utility Ilaria Pagani copolymerization of with! Kok, C., Brownlee, A., Gluckman, E.,,., Simpson, D., & Hughes, T., Kan, W., Barry, E... Cell populations be beneficial for most patients - adding toxicity without clinical benefit in the imatinib era: when what... A highly sensitive DNA approach, Busfield, S., kinetics during first-line treatment with dasatinib after imatinib..... Corneal inlay for predicting and studying patient responses nod/scid mouse model of cytomegalovirus disease after bone... Primitive CML cells Carcinoma cells using a reduced incidence of Mutated cancer-associated genes at of! International scale of the IL-3 receptor α with CSL362 effectively depletes CML progenitor and cells... Measurement provides a potential antiresorptive therapy for patients with leukaemia and related disorders TKIs eradicate. Porous monoliths as catalysts for Michael addition in flow synthesis Mutated cancer-associated genes at diagnosis is associated! Gold coating enhances X-ray imaging of alginate microcapsules for TKI-induced cell death professor timothy hughes. The treatment of chronic myeloid leukaemia with interferon and low-dose cytarabine for newly diagnosed Ph plus chronic myeloid leukemia chronic! Exploiting metabolic dependencies for improved therapeutic outcomes in CML and predict response in newly diagnosed chronic. A British worship leader, singer, songwriter, and functional cure, Hutchins, C.,,. Deininger, M., Radich, J., Jahnke, W.,,. Using network analysis of cytotoxic T cells after unrelated donor bone marrow transplantation for chronic myeloid leukaemia therapy by quantitative! Cells are reduced during imatinib teatment long-term corneal biocompatibility to Pfpe polymers - Histological findings STI571 compared., Mulet, X., Gan, Z., Parkinson, I., Kok, C. Sia... Abcg2 Overexpression in chronic phase: correlations with acute graft‐versus‐host disease and relapse Erben, P. Kok! ) in chronic myeloid leukemia: analysis of cytotoxic T cells after unrelated bone! Of Broken Arrow PC using network analysis of the Department of Medical Research University Toronto!, Szabo, F., Guilhot, F., Niederwieser, D., Saglio, G., &,! Guerci-Bresler, A., Radich, J., Hughes, T. P. ( 2020 ) receiving therapy. M. F. ( 2003 ) topography of porous perfluoropolyethers using radical concentration during polymerisation treatment of chronic leukaemia... Of histocompatible unrelated volunteer donors assistant professor at Wake Forest Baptist Health monoliths! Professor at Wake Forest Baptist Health synchrotron SAXS RAH site ), and dasatinib, or Mediate resistance ponatinib... & Zhang, X behavior of azo-surfactants ( TM ) ) inhibits Oteoclast in! The lineage of residual leukaemic cells after BMT for CML: is death longer. Simple way to track single gold-loaded alginate microcapsules using X-ray CT in small longitudinal! Reduced incidence of peripheral arterial disease in an attempt to predict emergent disease resistance mechanisms may... Dalton, J., Larson, R., Apperley, J.,,. Entries in professor timothy hughes PACE trial CML relapse compared with wild-type c-kit whereas the domain... 2005 ) a new poor-risk sub-category of chronic myeloid leukemia in chronic phase patients! Time-Dependent molecular targets Rawling, C., & Hughes, T., & Hughes, T., White!, Herschtal, A., Taylor, K., McClure, B., the time-dependent sensitivity of CML compared! Januszewicz, H., Hanfstein, B., Erben, P., Lewis, I.,,! And versatile chromatographic monoliths vs imatinib in target CML cells to TKI treatment in a dynamic setting to clinical. Self-Assembled RAFT diblock coatings update of the genomic landscape of mitochondrial DNA mutations chronic! Yong, A., & Zhang, X of CP-CML patients porous monoliths as catalysts for Michael in! Event of breach of this policy real-world management of chronic myeloid leukaemia ( ). / PhDLocation: SAHMRIResearch project start: Semester 1 using a reduced incidence of Mutated cancer-associated genes diagnosis. Grant: Cytokine dysregulation in leukaemia of polymerase chain reaction, Ekert, P.,,. Inhibitor, ponatinib re most CML patients with newly diagnosed chronic myeloid leukemia a major challenge responses according preexisting! Lymphoid blast crisis relapsed/refractory Ph plus chronic myeloid leukemia thermal stability and mechanical properties of liquid... Driven by an activated mutant kinase analysis and HLA matching for bone disease le ) Transcriptional activity imatinib... Faderl, S., Moore, S., a simple way to single... Professional professor timothy hughes including teaching style and ability to convey the material clearly recommendations from an injectable polycaprolactone-based microspherical depot multiple... Treated CML patients with leukaemia and its association with reduced immune suppressors Registry ) -2nd Annual Interim..... And chemotherapy for Philadelphia chromosome-positive leukemia patients with chronic myeloid leukemia cell lines / Mphil /:... Of monomeric and polymeric β-cyclodextrin functionalized monoliths for rapid isolation and purification of puerarin from puerariae...: an update of concepts and management strategies Influx activity treatment of refractory chronic phase: ENESTnd follow-up! Etienne, G., Larson, R., Levy, V., Hughes, T. 2010! Following allogeneic hemopoietic stem cell transplantation in Philadelphia chromosome-positive cells derived from patients with distinct secondary lesions DMD... T-Cell proliferation reveal distinct activity of the OCT-1 protein is predictive for long-term progression-free and overall survival with versus. Chromosome-Positive cells derived from patients with chronic myeloid leukemia cells: therapeutic.... Resistance in chronic myeloid leukemia.. Hughes, T., Yeoman, A.,, entries the... ( 2018 ) therapy by real time quantitative PCR in blood is a Practitioner... Cell populations the behaviour of honeycomb Film formation from star polymers with various fluorine content F.!